Evidence map›Paper›PMID 30293079›Full record

ArticleMedical principles and practice : international journal of the Kuwait University, Health Science Centre2018

Investigation of Therapeutic Effects of Erdosteine on Polycystic Ovary Syndrome in a Rat Model.

Atilla Karateke, Recep Dokuyucu, Hatice Dogan, Tumay Ozgur, Zeynel Abidin Tas, Okan Tutuk, Gokhan Agturk, Cemil Tumer

Open access · diamondAbstract readComparative Study
In one paragraph

Article in Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Regulation of estrous cycle byAnatomy & cell biology · 2019
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Atilla KaratekeDepartment of Obstetrics and Gynecology, Reyhanli Sevgi Hospital, Hatay, Turkey.
Recep DokuyucuDepartment of Physiology, Medical Specialty Training Center, Ankara, Turkeydrecepfatih@gmail.com.
Hatice DoganDepartment of Physiology, School of Medicine, Mustafa Kemal University, Hatay, Turkey.
Tumay OzgurDepartment of Pathology, School of Medicine, Mustafa Kemal University, Hatay, Turkey.
Zeynel Abidin TasDepartment of Pathology, School of Medicine, Mustafa Kemal University, Hatay, Turkey.
Okan TutukDepartment of Physiology, School of Medicine, Mustafa Kemal University, Hatay, Turkey.
Gokhan AgturkDepartment of Physiology, School of Medicine, Mustafa Kemal University, Hatay, Turkey.
Cemil TumerDepartment of Physiology, School of Medicine, Mustafa Kemal University, Hatay, Turkey.
Mustafa Kemal University · TRMinistry of Health · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePolycystic ovary syndrome (PCOS) is a serious endocrine disorder. In the present study, we investigated the therapeutic effects of erdosteine in letrozole-induced PCOS in rats.

methodsThirty-two Wistar albino female rats were grouped as control group (C), PCOS group (PCOS), PCOS-metformin group (PCOS+MET), and PCOS-erdosteine group (PCOS+Erd). PCOS was induced by administering letrozole; such rats presented with sex hormone disorder, abnormal estrous cycles determined by daily vaginal smear, large cystic follicles, and increasing fasting insulin levels. After induction of PCOS, metformin (500 mg/kg/day) and erdosteine (100 mg/kg/day) were given orally to the treatment groups for 30 days. Serum concentrations of glucose, total cholesterol, low- and high-density lipoprotein, triglyceride, as well as the total oxidant and antioxidant status, oxidative stress index, circulating estrone (E1), estradiol (E2), testosterone, and androstenedione were evaluated. The ovaries were graded histologically.

resultsWeights of ovarian tissues (p < 0.05) and the number of atretic follicles (p < 0.001) and cystic follicles (p < 0.01) decreased in the PCOS+Erd group; the corpus luteum number was significantly higher in the PCOS+Erd group (p < 0.01) as compared with the PCOS group. Lipid parameters (total-C, LDL-C, and TG), E1 (estrone), E1/E2 ratio, testosterone, and androstenedione significantly decreased, while HDL-C and E2 (estradiol) significantly increased in the PCOS+Erd group as compared with the PCOS group. Moreover glucose, insulin, and HOMA-IR were reduced with treatment of erdosteine (p > 0.05, p < 0.001, and p < 0.001, respectively).

conclusionIt is suggested that erdosteine may be used in the treatment of PCOS as an alternative to metformin. It appears that our findings might be supported by clinical and molecular studies.

Indexed as

Analysis of VarianceAnimalsBlood GlucoseCholesterolDisease Models, AnimalEstroneExpectorantsFemaleHypoglycemic AgentsInsulin ResistanceMetforminOvaryOxidative StressPolycystic Ovary SyndromeRandom AllocationRatsBlood GlucoseCholesterolerdosteineEstroneExpectorantsHypoglycemic AgentsMetforminThioglycolatesThiophenesErdosteineLetrozoleMetforminPolycystic ovary syndrome

Identifiers

PMID30293079
PMCPMC6422144
OpenAlexW2897567577

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.